Ed Mathers
InvestorPartner at New Enterprise Associates (NEA) · Board director at Senti Biosciences · Board director at Affinia Therapeutics · Board director at Curzion Pharmaceuticals Inc
Maryland
Writes $2M – $50M checks · typically $25M
About
Ed Mathers is a Partner on NEA's healthcare team, where he has worked since 2008, focusing on biotechnology and specialty pharmaceuticals investments. Before NEA, he was EVP of Corporate Development and Venture at MedImmune, contributing to its 2007 sale to AstraZeneca, and previously held roles at Inhale Therapeutic Systems and Glaxo Wellcome (now GSK). His investment interests include gene therapy, nonviral gene therapy, RNA editing, and immunology and inflammation.
Contact· self-published, not guessed
Invests in
Biotech
Board director at Senti Biosciences
Intro paths
In turn, Ed can intro founders to Senti Biosciences's investors below.
Senti Biosciences's investors · 11
Co-founders at Senti Biosciences
Board director at Affinia Therapeutics
Intro paths
In turn, Ed can intro founders to Affinia Therapeutics's investors below.
Affinia Therapeutics's investors · 8
Co-founders at Affinia Therapeutics
Board director at Curzion Pharmaceuticals Inc
Intro paths
In turn, Ed can intro founders to Curzion Pharmaceuticals Inc's investors below.
Curzion Pharmaceuticals Inc's investors · 2
Experience
- New Enterprise AssociatesPartnercurrent2008 — present
- New Enterprise AssociatesPartnercurrent2008 — present
- MedImmuneExec VP Corporate Development and Venture2002 — 2008
- GlaxoVP1985 — 1999
Deals · 6
Curzion Pharmaceuticals IncBoard seat
via New Enterprise Associates (NEA) · filed Jul 2019 · $3.5M raise
Mirum PharmaceuticalsBoard seat
via New Enterprise Associates (NEA) · filed Nov 2018 · $120.1M raise
Senti BiosciencesBoard seat
via New Enterprise Associates (NEA) · filed Feb 2018 · $53.4M raise
AkouosBoard seat
via New Enterprise Associates (NEA) · filed Nov 2017 · $7.6M raise
SynlogicBoard seat
via New Enterprise Associates (NEA) · filed Feb 2016 · $40.6M raise
Envisia TherapeuticsBoard seat
via New Enterprise Associates (NEA) · filed Oct 2015 · $5.1M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at New Enterprise Associates (NEA)
Network10
Investors connected to Ed in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Ed Mathers?
- Ed Mathers is a Partner on NEA's healthcare team, where he has worked since 2008, focusing on biotechnology and specialty pharmaceuticals investments. Before NEA, he was EVP of Corporate Development and Venture at MedImmune, contributing to its 2007 sale to AstraZeneca, and previously held roles at Inhale Therapeutic Systems and Glaxo Wellcome (now GSK). His investment interests include gene therapy, nonviral gene therapy, RNA editing, and immunology and inflammation.
- Where does Ed Mathers work?
- Ed Mathers is Partner at New Enterprise Associates (NEA) and Board director at Senti Biosciences and Board director at Affinia Therapeutics and Board director at Curzion Pharmaceuticals Inc.
- What does Ed Mathers invest in?
- Ed Mathers invests in Biotech.
- What check size does Ed Mathers write?
- Ed Mathers typically writes checks of $2M – $50M.
- What boards does Ed Mathers sit on?
- Ed Mathers holds tracked board seats at Akouos, Curzion Pharmaceuticals Inc, Envisia Therapeutics, Mirum Pharmaceuticals, Senti Biosciences, Synlogic.
- Where did Ed Mathers go to school?
- Ed Mathers studied at NC State University (Bachelor of Science (BS), Chemistry).
Same school
Also attended NC State University90
+ 84 more
Shared employers
Also worked at MedImmune10
+ 4 more
Also worked at Glaxo116
+ 110 more